To test the role of Stat3 in overriding dasatinib inhibition, we treated the RCC cells with CYT387 (Momelotinub ®), a JAK-STAT inhibitor that is currently in clinical trials for myeloproliferative neoplasia [40]. This evidence concerns the gene SOAT1 and renal cell carcinoma.